Kazia Therapeutics Limited (ASX:KZA)
Kazia Therapeutics Limited is an Australia-based oncology-focused drug development company. The Company collaborates with clinicians, scientists, and researchers across the world for the development of cancer treatment. The Company’s product candidates include Paxalisib and EVT801. Paxalisib (GDC-0084) is invented by Genentech, Inc (South San Francisco, CA). Genentech, Inc is a developer of new cancer medicines across the world. The Company entered into a license agreement with Genentech. EVT801 targets angiogenesis, the formation of new blood vessels around a tumor. EVT801 is invented by Sanofi SA (Paris, France), and licensed to Evotec SE (Hamburg, Germany). The Company entered into a license agreement with Evotec. EVT801 is ready for Phase I clinical trial.